AOCC 2020 Virtual Congress

S10. Biologics and small molecules in 2020

Room 1, December 17 (Thu) , 09:00-10:30

Chairs Toshifumi Hibi, Kitasato University Kitasato Institute Hospital, Japan
Suk-Kyun Yang, University of Ulsan, Korea

09:00-09:20	Anti-TNFs: Old school or still gold standard? Makoto Naganuma, Kansai Medical University, Japan
09:20-09:40	Emerging biologics: What will be a new hero? Edward V. Loftus, Jr., Mayo Clinic, USA
09:40-10:00	Small molecules: Which are the most promising? Laurent Peyrin-Biroulet, Nancy University Hospital, France
10:00-10:15	Higher anti-tumour necrosis factor-alpha drug levels are associated with improved radiological outcomes in patients with perianal fistulising Crohn's disease: A retrospective multi-centre study Michael De Gregorio, St Vincent's Hospital Melbourne, Australia
10:15-10:30	Real-world effectiveness and safety of vedolizumab therapy for inflammatory bowel disease in Taiwan: Results from the TSIBD registry (VIOLET Study) Wei-Chen Lin, Mackay Memorial Hospital, Taiwan

SS06. Multilayered remission in IBD, is it time to be more ambitious?

Room 2, December 17 (Thu) , 09:30-10:30

Chairs Chang-Hun Yang, Dongguk University, Korea
Jiaming Qian, Chinese Academy of Medical Sciences and Peking Union Medical College, China

09:30-10:00	Why target multilayered remission in IBD? Takanori Kanai, Keio University, Japan
10:00-10:30	What does it look like in IBD? Byong Duk Ye, University of Ulsan, Korea

S11. Challenges in special situations: Experts share hot tips

Room 3, December 17 (Thu) , 09:00-10:30

Chairs Sung-Ae Jung, Ewha Womans University, Korea
Jose D. Sollano, University of Santo Tomas, Philippines

09:00-09:20	Ulcerative colitis in the elderly: Essentials for clinical care Masaaki Higashiyama, National Defense Medical College, Japan
09:20-09:40	Clinical care pathway for pregnancy in IBD Rupert Leong, University of Sydney, Australia
09:40-10:00	Management of IBD in COVID-19 pandemic era Yan Chen, Zhejiang University, China
10:00-10:15	Risk of vertebral and hip fracture in patients with inflammatory bowel diseases: A nationwide population-based study Hyung Jin Ahn, Asan Medical Center, Korea
10:15-10:30	Impact of the COVID-19 pandemic on disease and psychological outcomes: A multi-national longitudinal study in inflammatory bowel disease Ines A Trindade, CINEICC, University of Coimbra, Portugal

S12. Endoscopy in IBD: Seeing more and intervening better

Room 1, December 17 (Thu) , 10:50-12:20

Chairs Jong Hun Lee, Dong-A Unviersity, Korea
Haruhiko Ogata, Keio University, Japan

10:50-11:10	Recent progress in the endoscopic scoring system Vineet Ahuja, All India Institute of Medical Sciences, India
11:10-11:30	Appropriate use of small bowel endoscopy Jinsu Kim, The Catholic University of Korea, Korea
11:30-11:50	The present and future of endoscopic intervention Kenji Watanabe, Hyogo College of Medicine, Japan
11:50-12:05	Disease activity monitoring and therapeutic optimization using conventional and magnifying endoscopy in patients with ulcerative colitis in clinical remission Katsuyoshi Ando, Asahikawa Medical University, Japan
12:05-12:20	When less is more and more is less; the inter-rater reliability of the endoscopic findings of pouchitis Zaid S Ardalan, Alfred Health and Monash University, Australia

S13. Optimal therapeutic strategies: Thinking out of the box

Room 2, December 17 (Thu) , 10:50-12:20

Chairs Hyunsoo Kim, Yonsei University Wonju, Korea
Cheng-Tang Chiu, Chang Gung University, Taiwan

10:50-11:10	Choosing the right therapy after conventional treatment failure Chang Hwan Choi, Chung-Ang University, Korea
11:10-11:30	Controversies and solutions in non-responders to anti-TNF Mark Silverberg, Mount Sinai Hospital, Canada
11:30-11:50	De-escalation of therapy in patients with quiescent IBD Taku Kobayashi, Kitasato University Kitasato Institute Hospital, Japan
11:50-12:05	Vedolizumab is superior to anti-tumour necrosis factor agents as a first-line biological agent but not as a second-line biological agent in moderate to severe ulcerative colitis Aviv Pudipeddi, Concord Repatriation General Hospital, Australia
12:05-12:20	Upfront surgery versus initial anti-TNF therapy for structural bowel damage in Crohns disease Wenwei Qian, Jinling Hospital, China

S14. Asian guideline for IBD management

Room 3, December 17 (Thu) , 10:50-12:20

Chairs Jiaming Qian, Chinese Academy of Medical Sciences and Peking Union Medical College, China
Hyun-Soo Kim, Chonnam National University, Korea

10:50-11:10	International guidelines in Asia: Are they feasible and necessary? Katsuyoshi Matsuoka, Toho University Sakura Medical Center, Japan
11:10-11:30	Lessons from ECCO for developing international guidelines Joana Torres, Hospital Beatriz Ângelo, Portugal
11:30-11:50	How to develop Asian guidelines for IBD? Dong Il Park, Sungkyunkwan University, Korea
11:50-12:20	Discussion

SS07. Raising the bar in ulcerative colitis treatment

Room 1, December 17 (Thu) , 12:20-13:20

Chairs Suk-Kyun Yang, University of Ulsan, Korea
Mamoru Watanabe, Tokyo Medical and Dental University, Japan

12:20-12:45	Adopting histological healing as next therapeutic target: are we ready? Young-Ho Kim, Sungkyunkwan University, Korea
12:45-13:20	Clinical evidence of ustekinumab in ulcerative colitis Miguel Regueiro, Cleveland Clinic, USA

SS08. Optimizing outcomes through targeting gut and systemic inflammation in ulcerative colitis

Room 2, December 17 (Thu) , 12:20-13:20

Chairs Jau-Min Wong, National Taiwan University Hospital, Taiwan
Seun Ja Park, Kosin University, Korea

12:20-12:50	Tight monitoring & inflammation control in ulcerative colitis Jae Hee Cheon, Yonsei University, Korea
12:50-13:20	Optimizing outcome through targeting systemic inflammation in ulcerative colitis with anti-TNF Tae Oh Kim, Inje University, Korea

SS09. JAK inhibition in UC: Focus on tofacitinib

Room 3, December 17 (Thu) , 12:20-13:20

Chairs Hyo Jong Kim, Kyung Hee University, Korea
Toshifumi Hibi, Kitasato University Kitasato Institute Hospital, Japan

12:20-12:50	Tofacitinib in UC: Exploring the efficacy and safety profile Laurent Peyrin-Biroulet, Nancy University Hospital, France
12:50-13:20	Practicalities of Tofacitinib in UC: Dosing and monitoring in appropriate patients Bora Keum, Korea University, Korea

PL. AOCC Plenary Session (Part 1)

Room 1, December 17 (Thu) , 13:40-14:25

Chairs Joo Sung Kim, Seoul National University, Korea
Takanori Kanai, Keio University, Japan

13:40-13:55	Multiscale 3D imaging of whole gut enteric nervous system in mouse and human using tissue clearing and its applications in IBD patients Young Hyun Yun, Seoul National University, Korea
13:55-14:10	Hsa_circRNA_102610 promotes growth and TGF-β1 induced EMT of intestinal epithelial cells by sponging hsa_miR-130a-3p Zhi Pang, Suzhou Municipal Hospital, China
14:10-14:25	Personalised nanomedicine: Precision nanotherapy based in-vitro and in-vivo paradigm for reducing severity of inflammation in acute experimental ulcerative colitis Anas Ahmad, Institute of Nano Science and Technology (INST), India

PL. AOCC Plenary Session (Part 2)

Room 1, December 17 (Thu) , 14:25-15:10

Chairs Minhu Chen, The First Affiliated Hospital, Sun Yat-sen University, China
Byung Ik Jang, Yeungnam University, Korea

14:25-14:40	Host genetic and gut microbial signatures in familial inflammatory bowel disease Ga Young Shin, Kyung Hee University Medical Center, Korea
14:40-14:55	Efficacy and safety of Filgotinib as induction therapy for patients with moderately to severely active ulcerative colitis: Results from the phase 2b/3 SELECTION study Hyo Jong Kim, Kyung Hee University Hospital, Korea
14:55-15:10	Pathway of focal adhesion and its relevant circRNAs and lncRNAs are involved with perianal Crohn's disease Shi-Xue Dai, Guangdong Provincial People's Hospital, China

S15. Current IBD care in Asia: Real-life situation

Room 2, December 17 (Thu) , 13:40-15:10

Chairs Eun Young Kim, Catholic University of Daegu, Korea
Ajit Sood, Dayanand Medical College and Hospital, India

13:40-14:00	Diagnosis of IBD - Asian perspectives Han Hee Lee, The Catholic University of Korea, Korea
14:00-14:20	Treatment of IBD Eun Mi Song, Ewha Womans University, Korea
14:20-14:40	Infections in IBD Seong-Joon Koh, Seoul National University, Korea
14:40-15:00	Vaccination in IBD Subum Park, Pusan National University, Korea
15:00-15:10	Discussion

S16. Tailored care for pediatric IBD: Children growing up

Room 3, December 17 (Thu) , 13:40-15:10

Chairs Byung-Ho Choe, Kyungpook National University, Korea
Marion Aw, National University of Singapore, Singapore

13:40-14:00	Infantile and very-early-onset IBD Jin Soo Moon, Seoul National University, Korea
14:00-14:20	Transition care of adolescents with IBD Marion Aw, National University of Singapore, Singapore
14:20-14:40	Personalized treatment in pediatric IBD Katsuhiro Arai, National Center for Child Health and Development, Japan
14:40-14:55	Clinical implication of VEOIBD (Very Early Onset Inflammatory Bowel Disease) gene panel on patients with intestinal inflammation Min Soo Kim, Seoul National University Hospital, Korea
14:55-15:10	Identification of immune landscapes and molecular subtypes in pediatric Crohn's disease Shiyu Xiao, Peking University Third Hospital, China

S17. Toward a systemic approach with precision medicine

Room 1, December 17 (Thu) , 15:30-17:00

Chairs Hong Yang, Peking Union Medical College Hospital Chinese Academy of Medical Sciences, China
Seung-Jae Myung, University of Ulsan, Korea

15:30-15:50	How can we integrate multiomics and clinical data to predict disease course? Dermot P.B. McGovern, Cedars-Sinai Medical Center, USA
15:50-16:10	How can we predict drug responses in the era of biologics? Chang Soo Eun, Hanyang University, Korea
16:10-16:30	How can we use microbiome data for precision medicine? Harry Sokol, Saint-Antoine Hospital, France
16:30-16:45	DNA methylation profiles accurately predict response to vedolizumab and remain stable during induction and maintenance treatment in Crohns disease Vincent Wilhelmus Joustra, Amsterdam UMC location AMC, Netherlands
16:45-17:00	A novel model for predicting the efficacy of infliximab in ulcerative colitis patients based on random forest and artificial neural network Jing Feng, Renji Hospital, China

S18. KASID-GEST Joint Symposium

Room 2, December 17 (Thu) , 15:30-17:00

Chairs Jeong-Sik Byeon, University of Ulsan, Korea
Han-Mo Chiu, National Taiwan University, Taiwan

15:30-15:50	Evolving epidemiology of colitis-associated cancer Hyun Gun Kim, Soon Chun Hyang University, Korea
15:50-16:10	Surveillance endoscopy for detection of dysplasia: Chromoendoscopy or other technologies? Tien-Yu Huang, Tri-Service General Hospital, Taiwan
16:10-16:30	Endoscopic treatment of colitis-associated dysplasia/cancer Dong-Hoon Yang, University of Ulsan, Korea
16:30-16:50	Chemoprevention of colitis-associated dysplasia/cancer in IBD Hsu-Heng Yen, Changhua Christian Hospital, Taiwan
16:50-17:00	Discussion

S19. Region-specific Forum

Room 3, December 17 (Thu) , 15:30-17:00

Chairs Byong Duk Ye, University of Ulsan, Korea
Pises Pisespongsa, Bumrungrad International Hospital, Thailand

15:30-15:45	Common colonic disease in Mongolia Bayasgalan Luvsandagva, Mongolian National University of Medical Sciences, Mongolia
15:45-16:00	Double balloon enteroscopy to diagnose small bowel diseases at Bach Mai Hospital, Hanoi, Vietnam Nguyen Hoai Nam, Bach Mai Hospital, Vietnam
16:00-16:15	Inflammatory bowel disease registry in low incidence country: Indonesia experience Murdani Abdullah, Dr. Cipto Mangunkusumo, Indonesia
16:15-16:30	Inflammatory bowel disease in Thailand in the last 2 decades - patterns of diagnosis, treatment, and outcomes Julajak Limsrivilai, Siriraj Hospital, Mahidol University, Thailand
16:30-17:00	Discussion

Scientific Program